Trulieve Cannabis Corp. (TRLV) AI Stock Analysis

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. It cultivates, processes, manufactures, and distributes cannabis products to its dispensaries and through home delivery. Its product lineup includes flowers, edibles, vapes, oral products, topicals, concentrates, and accessories sold under brands such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One. The company runs dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It also operates cultivation and processing facilities across Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia.

Revenue moved from $1.22B in FY2022 to $1.13B in FY2023, $1.19B in FY2024, and $1.18B in FY2025, registering a 3-year revenue CAGR of -1.0%. Gross margin expanded from 56.6% in FY2022 to 60.2% in FY2025, and operating margin rose to 12.6% in FY2025. Net income remained negative across the period, landing at -$116.4M in FY2025 compared to -$526.8M in FY2023 and -$246.1M in FY2022. For the trailing twelve months ended June 30, 2026, revenue stood at $1.14B, with quarterly revenue growth falling 10.3% year-over-year and diluted EPS at -$2.43.

As of June 30, 2026, Trulieve held $325.4M in cash and short-term investments and $577.3M in total debt, resulting in net debt of $251.8M. Shareholders' equity was $767.5M and total assets were $2.08B. The company maintained a debt-to-equity ratio of 0.75 and a current ratio of 5.94. In FY2025, operating cash flow reached $272.8M, capital expenditures were $60.5M, and free cash flow stood at $212.3M.

TRLV traded at a market capitalization of $1.93B and an enterprise value of $2.65B as of October 16, 2026. Its forward P/E ratio of 22.9x is higher than the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 1.7x and EV/EBITDA of 6.1x compare to peer medians of 4.1x and 12.0x, respectively. The stock closed at $10.01 on October 16, 2026, trading between a 52-week low of $7.17 and a 52-week high of $13.28, with a beta of 1.80.

Wall Street coverage includes 6 Strong Buy ratings, 1 Buy, and no Hold or Sell recommendations. The mean price target is $18.18, which is 81.6% above the last close of $10.01. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.01B and an EPS of -$1.82. For the following fiscal year, 3 analysts project revenue of $936.4M and EPS of $0.56. Trulieve beat EPS expectations in 3 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of Trulieve Cannabis Corp. (TRLV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TRLV income statement, TRLV balance sheet, TRLV key metrics, TRLV analyst forecast, TRLV chart. See the TRLV stock overview for the latest quote and news.